{"disease":{"id":"myeloid-leukemia","name":"myeloid leukemia"},"drugs":{"marketed":[{"drug_id":"venetoclax","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venclexta","generic_name":"venetoclax","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"BCL-2 Inhibitor [EPC]","quality_score":80,"revenue":"2583","mechanism":"Venclexta is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein."},{"drug_id":"nivestym","indication_name":"Relapsed acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"nivestym","indication_name":"Refractory acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"cyclophosphamide","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"asciminib","indication_name":"Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"","quality_score":69,"revenue":"894","mechanism":"Scemblix works by blocking the ABL1 enzyme, which is involved in the growth and survival of cancer cells."},{"drug_id":"bosutinib","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"bosutinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif works by blocking the activity of a specific enzyme called tyrosine-protein kinase ABL1, which is involved in the growth and survival of cancer cells."},{"drug_id":"bosulif","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bosulif","generic_name":"Bosutinib Monohydrate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"Kinase Inhibitor","quality_score":75,"revenue":"611","mechanism":"Bosulif blocks the abnormal tyrosine kinase activity in cancer cells, inhibiting their growth and proliferation."},{"drug_id":"gilteritinib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xospata","generic_name":"GILTERITINIB","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Leukocyte tyrosine kinase receptor","drug_class":"","quality_score":65,"revenue":"600","mechanism":"Xospata works by blocking the activity of a specific enzyme called Leukocyte tyrosine kinase receptor."},{"drug_id":"dasatinib","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"dasatinib","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"nilotinib","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tasigna","generic_name":"NILOTINIB","company_name":"Cipla","drug_phase":"marketed","molecular_target":"Bcr/Abl fusion protein","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"400","mechanism":"Tasigna works by blocking the abnormal Bcr/Abl protein that drives the growth of cancer cells in CML."},{"drug_id":"midostaurin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rydapt","generic_name":"MIDOSTAURIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Mast/stem cell growth factor receptor Kit","drug_class":"Kinase Inhibitor [EPC]","quality_score":62,"revenue":"200","mechanism":"Rydapt blocks the activity of the Kit receptor, which is involved in the growth and survival of cancer cells."},{"drug_id":"glasdegib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daurismo","generic_name":"glasdegib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Smoothened homolog","drug_class":"Hedgehog Pathway Inhibitor [EPC]","quality_score":10,"revenue":"150","mechanism":"Daurismo works by blocking the Smoothened homolog, a protein involved in the Hedgehog signaling pathway, which is often dysregulated in cancer cells."},{"drug_id":"daurismo","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daurismo","generic_name":"Glasdegib Maleate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Smoothened (transmembrane protein)","drug_class":"Hedgehog pathway inhibitor","quality_score":10,"revenue":"150","mechanism":"Glasdegib inhibits Smoothened, a transmembrane protein in the Hedgehog signaling pathway."},{"drug_id":"gemtuzumab-ozogamicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"gemtuzumab-ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"100","mechanism":"Mylotarg works by binding to CD33 on cancer cells and releasing a toxic compound that kills the cells."},{"drug_id":"mylotarg","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"Gemtuzumab Ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD33 antigen","drug_class":"Antibody-drug conjugate (ADC)","quality_score":10,"revenue":"100","mechanism":"CD33-directed antibody-drug conjugate that delivers cytotoxic calicheamicin to tumor cells."},{"drug_id":"gemtuzumab","indication_name":"newly-diagnosed CD33-positive acute myeloid leukemia (AML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"GEMTUZUMAB","company_name":"Wyeth Pharms Inc","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"100","mechanism":"Mylotarg targets and binds to CD33-positive cancer cells, delivering a cytotoxic agent to destroy them."},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"xospata","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xospata","company_name":"French Innovative Leukemia Organisation","drug_phase":"marketed","molecular_target":"ADP/ATP translocase 2, ADP/ATP translocase 3, Bone morphogenetic protein receptor type-1B","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"neupogen","indication_name":"Refractory acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"neupogen","indication_name":"Relapsed acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"decitabine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dacogen","generic_name":"decitabine","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":58,"revenue":null,"mechanism":"Dacogen works by inhibiting the enzyme that adds methyl groups to DNA, which helps to restore normal gene function in cancer cells."},{"drug_id":"daunorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"daunorubicin","indication_name":"Blast crisis of chronic myeloidleukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"revumenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revuforj","generic_name":"REVUMENIB","company_name":"Syndax","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Revuforj works by inhibiting an enzyme that is involved in the growth and survival of cancer cells."},{"drug_id":"azacitidine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"mechlorethamine","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valchlor","generic_name":"MECHLORETHAMINE","company_name":"Recordati","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"quizartinib","indication_name":"Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanflyta","generic_name":"QUIZARTINIB","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Macrophage colony-stimulating factor 1 receptor","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Vanflyta works by blocking the macrophage colony-stimulating factor 1 receptor, which is involved in the growth and survival of cancer cells."},{"drug_id":"quizartinib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vanflyta","generic_name":"QUIZARTINIB","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Macrophage colony-stimulating factor 1 receptor","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Vanflyta works by blocking the macrophage colony-stimulating factor 1 receptor, which is involved in the growth and survival of cancer cells."},{"drug_id":"fludarabine-phosphate","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludara","generic_name":"FLUDARABINE PHOSPHATE","company_name":"Nihon Schering K.K.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fludara works by interfering with the production of DNA and RNA in cancer cells, ultimately leading to cell death."},{"drug_id":"omacetaxine-mepesuccinate","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synribo","generic_name":"OMACETAXINE MEPESUCCINATE","company_name":"Teva Pharms Intl","drug_phase":"marketed","molecular_target":"","drug_class":"omacetaxine mepesuccinate","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"vindesin","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vindesin","company_name":"The Lymphoma Academic Research Organisation","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"idarubicin-hydrochloride","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"Idarubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA, Topoisomerase II","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":61,"revenue":null,"mechanism":"Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals."},{"drug_id":"dacogen","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dacogen","company_name":"Mayo Clinic","drug_phase":"discontinued","molecular_target":"DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"daunorubicine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"daunorubicine","indication_name":"Blast crisis of chronic myeloidleukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"histamine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eramin","generic_name":"HISTAMINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"histamine","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"cytarabine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytarabine","generic_name":"Cytarabine","company_name":"Nippon Shinyaku Co., Ltd.","drug_phase":"marketed","molecular_target":"DNA polymerase","drug_class":"Antimetabolite","quality_score":72,"revenue":null,"mechanism":"Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase."},{"drug_id":"gleevec","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"gleevec","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"homoharringtonine","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Homoharringtonine","company_name":"ChemGenex Pharmaceuticals","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aclacinomycin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"aclacinomycin","company_name":"Chinese PLA General Hospital","drug_phase":"phase_3","molecular_target":"72 kDa type IV collagenase, DNA topoisomerase II, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":4,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"enasidenib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idhifa","generic_name":"ENASIDENIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Isocitrate dehydrogenase [NADP], mitochondrial","drug_class":"Isocitrate Dehydrogenase 2 Inhibitor","quality_score":59,"revenue":null,"mechanism":"Idhifa works by blocking the IDH2 enzyme, which is mutated in some AML cells, to prevent the production of a toxic metabolite that promotes cancer growth."},{"drug_id":"azacytidine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"azacytidine","company_name":"Assistance Publique Hopitaux De Marseille","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1, DNA (cytosine-5)-methyltransferase 3A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"vindesine","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eldisine","generic_name":"VINDESINE","company_name":"","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"vindesine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"aclarubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aclacur","generic_name":"ACLARUBICIN","company_name":"","drug_phase":"phase_3","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"aclarubicin","quality_score":null,"revenue":null,"mechanism":"Aclacur works by binding to the 5-hydroxytryptamine receptor 2B, which is involved in cell growth and proliferation."},{"drug_id":"mitoxantrone","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"uracil-mustard","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uramustin","generic_name":"URACIL MUSTARD","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"uracil mustard","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"part-c-met097","indication_name":"Treatment of Acute Myeloid Leukemia (AML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"part-c-met097","indication_name":"Treatment of Chronic Myeloid Leukemia (CML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of acute myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"hydroxyurea","indication_name":"Resistant chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYUREA","company_name":"","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"thioguanine","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thioguanine","generic_name":"thioguanine","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 1","drug_class":"thioguanine","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"ziftomenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Komzifti","generic_name":"ZIFTOMENIB","company_name":"Kura","drug_phase":"marketed","molecular_target":"","drug_class":"Menin Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells."},{"drug_id":"ziftomenib","indication_name":"relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Komzifti","generic_name":"ZIFTOMENIB","company_name":"Kura","drug_phase":"marketed","molecular_target":"","drug_class":"Menin Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Komzifti works by inhibiting the menin protein, which is involved in the regulation of gene expression in cancer cells."},{"drug_id":"asciminib-hydrochloride","indication_name":"Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB HYDROCHLORIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ABL1 kinase of BCR::ABL1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Asciminib binds to the ABL myristoyl pocket, inhibiting ABL1 kinase activity of BCR::ABL1, including mutant forms."},{"drug_id":"chembl-chembl1200976","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"DNA, topoisomerase II","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Idarubicin hydrochloride exerts its effects by forming DNA complexes, inhibiting nucleic acid synthesis, blocking topoisomerase II, and generating DNA-damaging free radicals."},{"drug_id":"imatinib","indication_name":"Blastic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"imatinib","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"gm-csf","indication_name":"Chronic Myeloid Leukemia (CML) in adult patients with Philadelphia chromosome-positive (Ph+) disease who are refractory or resistant to at least one prior tyrosine kinase inhibitor (TKI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Chronic Myeloid Leukemia (CML) in adult patients with Philadelphia chromosome-positive (Ph+) disease who are refractory or resistant to at least one prior tyrosine kinase inhibitor (TKI) therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gm-csf","indication_name":"Acute Myeloid Leukemia (AML) in adult patients 60 years or older with at least 30% bone marrow blasts and intermediate-2 or high-risk cytogenetic abnormalities by the European LeukemiaNet (ELN) classification","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gm-Csf","generic_name":"gm-csf","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GM-CSF receptor","drug_class":"cytokine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ivosidenib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tibsovo","generic_name":"IVOSIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"mutant IDH1","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Ivosidenib inhibits mutant IDH1, reducing 2-HG levels and promoting myeloid differentiation in AML."},{"drug_id":"aldesleukin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Proleukin","generic_name":"ALDESLEUKIN","company_name":"Chiron","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Lymphocyte Growth Factor [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"olutasidenib","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."},{"drug_id":"olutasidenib","indication_name":"Refractory acute myeloid leukemia with a susceptible IDH1 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."},{"drug_id":"olutasidenib","indication_name":"Relapsing acute myeloid leukemia with a susceptible IDH1 mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezlidhia","generic_name":"OLUTASIDENIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"mutated IDH1","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells."},{"drug_id":"doxorubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"idarubicin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Idarubicin works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death."},{"drug_id":"chembl-chembl1200796","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"fludarabin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludarabin","company_name":"Azienda Ospedaliera San Giovanni Battista","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxycarbamide","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamide","company_name":"University of Birmingham","drug_phase":"phase_3","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"proleukin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Proleukin","company_name":"University of Minnesota","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"siklos","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Siklos","company_name":"Theravia","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fludara","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fludara","company_name":"Celyad Oncology SA","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 5A, mitochondrial, DNA polymerase alpha catalytic subunit, Ribonucleoside-diphosphate reductase large subunit","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tasigna","indication_name":"Chronic phase chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasigna","company_name":"XSpray Microparticles","drug_phase":"marketed","molecular_target":"Ferrochelatase, mitochondrial, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase MRCK beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mitozantrone","indication_name":"Acute myeloid leukemia, disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xromi","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xromi","company_name":"Nova Laboratories Limited","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxycarbamid","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamid","company_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","drug_phase":"phase_2","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"idarubicin","indication_name":"Acute Myeloid Leukemia (AML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Idamycin Pfs","generic_name":"IDARUBICIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Idarubicin works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death."},{"drug_id":"omacetaxine","indication_name":"Chronic myeloid leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omacetaxine","company_name":"University of Illinois at Chicago","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Chronic myeloid leukemia (CML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute myeloid leukemia (AML) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":158,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01252485","title":"Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"University of Ulm","has_results":false},{"nct_id":"NCT03433521","title":"Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":15000,"lead_sponsor_name":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","has_results":false},{"nct_id":"NCT05541224","title":"A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers","phase":"","overall_status":"COMPLETED","enrollment_count":6917,"lead_sponsor_name":"PETHEMA Foundation","has_results":false},{"nct_id":"NCT04777916","title":"Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Acute Leukemia French Association","has_results":false},{"nct_id":"NCT05963061","title":"Chronic Myeloid Leukemia (CML) Real-Life Database","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT05476562","title":"Study Conducted Among Patients With CML","phase":"","overall_status":"COMPLETED","enrollment_count":3234,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06659224","title":"The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":2631,"lead_sponsor_name":"asmaa salama ibrahim","has_results":false},{"nct_id":"NCT00339664","title":"Analyses of Human Samples Collected in Clinical Trials","phase":"","overall_status":"COMPLETED","enrollment_count":2579,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00898079","title":"Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2545,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06692803","title":"Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":2043,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01005277","title":"Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT07150676","title":"Harmonized Clinical and Biological Database for Integrated Research Into the Management of Pediatric Acute Myeloid Leukemia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05564390","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07165535","title":"Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT03904134","title":"Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1753,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT01371981","title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1645,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT01595295","title":"Registry on Hypomethylating Agents in Myeloid Neoplasms","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","has_results":false},{"nct_id":"NCT01244750","title":"Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting","phase":"","overall_status":"COMPLETED","enrollment_count":1494,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06463639","title":"FLT3 Clonal Evolution in Patients With Acute Myeloid Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":1213,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT04293562","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1186,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03047083","title":"Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review","phase":"","overall_status":"COMPLETED","enrollment_count":1027,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06697600","title":"A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers","phase":"NA","overall_status":"RECRUITING","enrollment_count":1020,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT05312112","title":"Real World Outcomes Using Novel Agents for AML in the UK","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT06681363","title":"Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT04060485","title":"Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03839771","title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":968,"lead_sponsor_name":"Stichting Hemato-Oncologie voor Volwassenen Nederland","has_results":false},{"nct_id":"NCT04726241","title":"The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"PedAL BCU, LLC","has_results":false},{"nct_id":"NCT05444348","title":"Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)","phase":"NA","overall_status":"RECRUITING","enrollment_count":920,"lead_sponsor_name":"Christoffer Johansen","has_results":false},{"nct_id":"NCT03311815","title":"Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.","phase":"","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"PETHEMA Foundation","has_results":false},{"nct_id":"NCT06810791","title":"HVA vs IA/DA or VA in the Treatment of ND HR-AML","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":876,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT01596114","title":"European Stop Tyrosine Kinase Inhibitor Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":868,"lead_sponsor_name":"European LeukemiaNet","has_results":false},{"nct_id":"NCT04769947","title":"Italian Treatment Free Remission Registry","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Turin, Italy","has_results":false},{"nct_id":"NCT07150793","title":"A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":754,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01802333","title":"Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":754,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02085408","title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":727,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT01657604","title":"TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":717,"lead_sponsor_name":"University of Jena","has_results":false},{"nct_id":"NCT01191801","title":"Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":711,"lead_sponsor_name":"Sunesis Pharmaceuticals","has_results":true},{"nct_id":"NCT01929408","title":"Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients","phase":"","overall_status":"COMPLETED","enrollment_count":703,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04369287","title":"Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia","phase":"","overall_status":"UNKNOWN","enrollment_count":654,"lead_sponsor_name":"Istituto Clinico Humanitas","has_results":false},{"nct_id":"NCT04988555","title":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":606,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":false},{"nct_id":"NCT00893399","title":"Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"University of Ulm","has_results":false},{"nct_id":"NCT07463651","title":"MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":594,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05166135","title":"Latin American Real-world Study in Acute Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":589,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03257241","title":"A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":582,"lead_sponsor_name":"Polish Adult Leukemia Group","has_results":false},{"nct_id":"NCT00261846","title":"Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":571,"lead_sponsor_name":"Pfizer","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}